181 related articles for article (PubMed ID: 37968084)
1. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
[No Abstract] [Full Text] [Related]
2. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
3. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study.
Li T; Xu Y; Sun W; Yan W; Wang C; Hu T; Zhang X; Luo Z; Liu X; Chen Y
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678538
[TBL] [Abstract][Full Text] [Related]
6. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
8. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.
Anaya DA; Xing Y; Feng L; Huang X; Camacho LH; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Cormier JN
Cancer; 2008 May; 112(9):2030-7. PubMed ID: 18320602
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract][Full Text] [Related]
12. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
13. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
14. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
15. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C
J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688
[TBL] [Abstract][Full Text] [Related]
17. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
Agarwala SS; Lee SJ; Yip W; Rao UN; Tarhini AA; Cohen GI; Reintgen DS; Evans TL; Brell JM; Albertini MR; Atkins MB; Dakhil SR; Conry RM; Sosman JA; Flaherty LE; Sondak VK; Carson WE; Smylie MG; Pappo AS; Kefford RF; Kirkwood JM
J Clin Oncol; 2017 Mar; 35(8):885-892. PubMed ID: 28135150
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
20. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
